Clinical Updates
Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: Insights from the TEASE-1 Randomized Clinical Trial
This review synthesizes evidence from the TEASE-1 trial and related studies on gildeuretinol acetate, highlighting its safety profile and modest efficacy in slowing retinal atrophic lesion growth in Stargardt disease over 24 months.
